On the road to precision health: Brain-based biomarkers in autism spectrum disorder

  • Autism Research
Speaker Shafali Spurling Jeste, M.D.
University of California, Los Angeles
Date & Time


Location

Gerald D. Fischbach Auditorium
160 5th Avenue
New York, NY 10010 United States

Autism Research

Autism Research lectures bring together scientists and scholars to discuss diverse and important topics related to autism. The lectures are open to the public and are held at the Gerald D. Fischbach Auditorium at the Simons Foundation headquarters in New York City. Tea is served prior to each lecture.

 
On 7 February 2018, Shafali Spurling Jeste provided a topical overview of the current state of research in autism biomarkers. She shared data from studies of autism biomarkers in three key areas: early risk prediction (studies of high-risk infants), heterogeneity within the autism spectrum and genetically defined subgroups within autism. Finally, she discussed the challenges around clinical trial design and development and considered how more objective measures of brain function can improve clinical trials.

Her talk is part of the Simons Foundation Autism Research lecture series.

About the Lecture

Autism has well-established roots in disruptions during the development of neural networks. Functional neuroimaging methods, such as electroencephalography (EEG), can measure these brain changes, with such measurements serving as robust “biomarkers” of the condition. Studies of autism biomarkers can enhance our ability to predict atypical development early in infancy and can improve both the selection of trial participants and quantification of brain changes with treatment in clinical trials. However, autism biomarker studies face many challenges, from methods in data collection to the generalizability of findings to the broader autism spectrum.

In this lecture, Shafali Spurling Jeste provided a topical overview of the current state of research in autism biomarkers. She shared data from studies of autism biomarkers in three key areas: early risk prediction (studies of high-risk infants), heterogeneity within the autism spectrum and genetically defined subgroups within autism. Finally, she discussed the challenges around clinical trial design and development and considered how more objective measures of brain function can improve clinical trials.

About the Speaker

Shafali Spurling Jeste is a behavioral child neurologist specializing in autism and neurodevelopmental disorders. After earning her B.A. in philosophy from Yale University and an M.D. from Harvard Medical School, she completed both child neurology and developmental neuroscience fellowships at Boston Children’s Hospital. Since 2010, she has directed the biomarkers core of the University of California, Los Angeles, Center for Autism Research and Treatment. Her extensive research program integrates genetics with functional electroencephalography to inform early risk prediction, treatment targets and clinical trials in autism, motivated by the ultimate goal of improving treatments and outcomes in infants and children with autism.

Past Lectures

Autism genetics: Where have we been and where are we going?

Matthew State, M.D., Ph.D.Oberndorf Family Distinguished Professor and Chair, University of California, San Francisco

On April 10, 2018, Matthew State reviewed the progress that has been made in autism genetics over the past 10 years and the role that the Simons Simplex Collection (SSC) played in this (r)evolution. He also addressed the potential contribution of ongoing genomic studies including whole-genome sequencing as well as the challenges and opportunities of leveraging the genetic findings to identify pathophysiological mechanisms.

On the road to precision health: Brain-based biomarkers in autism spectrum disorder

Shafali Spurling Jeste, M.D.Associate Professor in Psychiatry, Neurology and Pediatrics, University of California, Los Angeles
Director, Developmental Neurophysiology Lab, Center for Autism Research and Treatment, University of California, Los Angeles

On 7 February 2018, Shafali Spurling Jeste provided a topical overview of the current state of research in autism biomarkers. She shared data from studies of autism biomarkers in three key areas: early risk prediction (studies of high-risk infants), heterogeneity within the autism spectrum and genetically defined subgroups within autism. Finally, she discussed the challenges around clinical trial design and development and considered how more objective measures of brain function can improve clinical trials.

Arousal, emotion regulation and challenging behaviors: Insights from the Autism Inpatient Collection

Matthew Siegel, M.D.Associate Professor of Psychiatry and Pediatrics, Tufts University
Vice President, Medical Affairs, Developmental Disorders Service, Maine Behavioral Healthcare

On 24 January 2018, Matthew Siegel drew upon a new resource, the Autism Inpatient Collection data set, to offer preliminary insights into the relationships between physiologic arousal, emotion dysregulation and the occurrence of challenging behaviors. Such behaviors may represent an attempt to modulate physiologic arousal in minimally verbal individuals with autism spectrum disorders.

Subscribe to our newsletter and receive SFARI funding announcements and news